<DOC>
	<DOCNO>NCT01136733</DOCNO>
	<brief_summary>This open-label , multicenter , Phase 1b/2 study lenvatinib alone combination everolimus subject unresectable advanced metastatic renal cell carcinoma follow one prior VEGF-targeted treatment .</brief_summary>
	<brief_title>A Study E7080 Alone , Combination With Everolimus Subjects With Unresectable Advanced Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor ( VEGF ) -Targeted Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Select Histologically confirm diagnosis renal cell carcinoma . Phase 2 : Histological cytological confirmation predominant clear cell RCC ( original tissue diagnosis RCC acceptable ) . Documented evidence unresectable advanced metastatic RCC . Phase 2 : Radiographic evidence disease progression accord modify Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Phase 2 : One prior vascular endothelial growth factor ( VEGF ) target treatment ( example , limited , sunitinib , sorafenib , pazopanib , bevacizumab , axitinib , vatalanib , AV951/tivozanib ) unresectable advanced metastatic RCC . Phase 2 : Measurable disease meeting follow criterion : . ) least 1 lesion great equal 1.5 cm long diameter nonlymph node great equal 1.5 cm short axis diameter lymph node serially measurable accord Modified RECIST 1.1 use computerize tomography/magnetic resonance imaging ( CT/MRI ) photography . Subjects must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Adequately control blood pressure ( BP ) without antihypertensive medication , define BP le equal 150/90 mmHg screen change antihypertensive medication within 1 week prior Screening Visit . Select Phase 1b Phase 2 specific per : Phase 1b : Subjects untreated unstable metastasis central nervous system ( CNS ) exclude . Subjects complete local therapy discontinue use steroid indication least 4 week prior commence treatment stability proven least 2 CT MRI scan obtain least 4 week apart eligible Phase 1b . Phase 2 : Subjects CNS ( e.g. , brain leptomeningeal ) metastasis exclude . Phase 2 : More one prior VEGFtargeted treatment unresectable advanced metastatic RCC . Phase 1b Phase 2 specific per : Phase 1b : Prior exposure lenvatinib . Phase 2 : Prior exposure lenvatinib mammalian target rapamycin ( mTOR ) inhibitor . Subjects received anticancer treatment within 21 day investigational agent within 30 day prior first dose study drug recover toxicity relate previous anticancer treatment . Major surgery within 3 week prior first dose study drug . Subjects great 1+ proteinuria urinalysis undergo 24hour urine collection quantitative assessment proteinuria . Subjects urine protein great equal 1 g/24hour ineligible . Uncontrolled diabetes define fast serum glucose 1.5 x ULN . Phase 2 : Active malignancy ( except renal cell carcinoma , melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) within past 24 month . Known intolerance study drug ( excipients ) and/or know hypersensitivity rapamycins ( e.g. , sirolimus , everolimus , temsirolimus ) excipients . Phase 1b : Subjects discontinue prior tyrosine kinase inhibitor due toxicity ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Unresectable advance metastatic renal cell carcinoma</keyword>
</DOC>